Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Deffered Revenue (2020)

Serina Therapeutics (SER) has disclosed Non-Current Deffered Revenue for 1 consecutive years, with $64000.0 as the latest value for Q4 2020.

  • Quarterly Non-Current Deffered Revenue changed N/A to $64000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $64000.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $64000.0 for FY2020, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $64000.0 in Q4 2020 for Serina Therapeutics.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $64000.0 in Q4 2020 to a low of $64000.0 in Q4 2020.